Thanks, Read Answer Asked by Harry on April 19, 2018 One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. Investors have until November 24, 2020 to seek an active role in this litigation. Bryan Lawlis, Ph.D., joined BioMarin’s Board in June 2007. He trained in internal medicine at the University of Utah and endocrinology/metabolism at the University of California at San Francisco. From November 2007 to May 2009, Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, a global ophthalmic medical device company that was acquired by Abbott in February 2009. Real-time discussion about BioMarin Pharmaceutical Inc. (BMRN) on CEO.CA, an investment chat community for Canada's small cap markets Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. 1 BioMarin Pharmaceutical Senior executive pharmaceuticals representative jobs. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that differences between the Phase 1/2 and Phase 3 study of … From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry . Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing. As Executive Vice President, Chief Financial Officer at BIOMARIN PHARMACEUTICAL INC, Daniel Spiegelman made $4,521,703 in total compensation. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction on Monday, December 28th. He previously served on the board of KaloBios Pharmaceuticals, Inc., a public biopharmaceutical company, from August 2013 until September 2014, and he acted as the Chairman of the scientific advisory board for Coherus from November 2012 to June 2016. Executive Medical Director at BioMarin Pharmaceutical Inc. San Francisco Bay Area . From 2007 to 2011, he also served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spin-off. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. Jean-Jacques Bienaimé joined BioMarin’s Board in May 2005, the same time that he became the Company’s Chief Executive Officer, … HF. BIOMARIN PHARMACEUTICAL INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Former Worldwide Vice President, Infectious Disease and Vaccines at Janssen Pharmaceuticals, Inc. Elizabeth McKee Anderson joined the Board in July 2019 and brings more than 30 years of leadership in biotechnology, pharmaceuticals, and vaccines. It has offices and facilities in the United States, South America, Asia, and Europe. San Diego, CA -- -- 01/18/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of BioMarin Pharmaceutical Inc..Investors who are current long term investors in BioMarin Pharmaceutical Inc… Prior to Johnson & Johnson, Ms. Anderson served as the Vice President and General Manager of Wyeth Lederle Vaccines from 1997 to 2002. Between January and September 2009, he was President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. From August 2011 to September 2017 he served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc, a private biotechnology company. Posted by Liza Goodheart on Jan 2nd, 2021. BIOMARIN PHARMACEUTICAL INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. BMRN - key executives, insider trading, ownership, revenue and average growth rates. The business had revenue of $476.78 million during the quarter, compared to analyst estimates of $454.64 million. ... Executive Vice President. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, December 28th. BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.It has offices and facilities in the United States, South America, Asia, and Europe.BioMarin's core business and research is in enzyme replacement therapies (ERTs). Of this total $93,750 was received as fees earned or paid in cash, $0 was received as non-stock incentive plan compensation, $0 was received as change in pension value and nonqualified deferred compensation earnings, $0 was received as options, $396,159 was … ), joined BioMarin’s Board in January 2016. Our purpose is the patient. The biotechnology company reported $4.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $4.02. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction on Monday, December 28th. From July 2001 to October 2008, Dr. Heron was Chair and Chief Executive Officer of Labcyte Inc., a private biotechnology company. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. Since November 2014, he has served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. Average pay of disclosed executives at BioMarin Pharmaceutical. BioMarin Pharmaceutical Inc. is a biotechnology company. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation (Aradigm), a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Mr. Meier holds a B.A. Dr. Lawlis holds board positions at three private companies: AbSci, LLC, Reform Biologics LLC and Sutro Biopharma, Inc. Join to Connect BioMarin Pharmaceutical Inc. University of Alberta. Robert A. Baffi President, Global Manufacturing amp; Technical … Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry . See who BioMarin Pharmaceutical Inc. has hired for this role. Since 2014, he has served on the scientific advisory board of the California Institute of Regenerative Medicine. An investigation on behalf of current long term investors in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares over possible breaches of fiduciary … Executive Regional Business Manager, Western Canada at BioMarin Pharmaceutical Inc Vancouver, Canada Area 500+ connections. Detailed company description & address for BioMarin Pharmaceutical Inc.. Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. Ten analysts have provided estimates for BioMarin Pharmaceutical’s earnings. Search job openings, see if they fit - company salaries, reviews, and more posted by BioMarin Pharmaceutical … Since October 2015, Dr. Lawlis has served as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN January … Apply on … Effective May 4, Dr. Guyer will succeed Robert Baffi, Ph.D., President, Global Manufacturing and Technical Operations, … Key Executives… Robert J. Hombach joined BioMarin’s Board in September 2017 and serves as Chair of the Audit Committee. BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases. Dr. Pyott serves as Chairman of Bioniz Therapeutics, Inc., a private biotechnology company, and serves on the board of Rani Therapeutics, LLC, a private biotechnology company. Dr. Lawlis holds a B.A. SAN RAFAEL, Calif., April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations. Dr. Lawlis has served on the board of Geron Corporation, a public biopharmaceutical company, since March 2012, and has served as a member of the board of Coherus Biosciences, Inc., a public biotechnology company (Coherus), since October 2014. Wedbush reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. His last position at Genentech, Inc. was Vice President of Process Sciences. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma, Inc. During 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc., a pharmaceutical company. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, December 28th. Following the transaction, the chief executive officer now directly owns 297,052 shares in the company, valued at $26,369,306.04. in chemistry from the University of Nottingham, United Kingdom. * biomarin pharmaceutical inc says ceo jean-jacques bienaimÉ's 2017 total compensation was $15.9 million versus $16.9 million in 2016 – sec filing Quote and financial data from Refinitiv. Mercer Global Advisors Inc. ADV now owns 26,251 shares of the biotechnology company’s stock valued at $1,997,000 after acquiring an additional 23,384 shares during the period. Previously, Dr. Pyott served on the board of Edwards Lifesciences Corp., a public medical device company, from 2000 to 2014. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by GenzymeCorporation). BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in … in chemistry with highest distinction, a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University. BioMarin Pharmaceutical Inc. San Rafael, CA 2 days ago Be among the first 25 applicants. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin Pharmaceutical Inc. (BMRN) View BMRN Profile; View Questions on BMRN; Add to favourite. That's a notable increase of 18% on last year. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. Posted by Liza Goodheart on Jan 2nd, 2021. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc. (formerly ICN Pharmaceuticals, Inc. (ICN)), from October 1999 to April 2002, and Senior Vice President & Treasurer from May 1998 to October 1999. A number of institutional investors and hedge funds have recently modified their holdings of the business. Between April 2002 and November 2007, Mr. Meier served continuously as Advanced Medical Optics’ Chief Financial Officer, while serving in a variety of additional senior operating roles. Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private early stage drug development company, from February 2009 until October 2015, and she continues to serve as member of that company’s board. She most recently served as Worldwide Vice President, Infectious Disease and Vaccines for Janssen Pharmaceuticals, a Johnson & Johnson company, where she directed the commercial development of an extensive portfolio of antivirals and vaccines with responsibility for global strategic marketing, market access, and global analytics for that division. A 1970 B.A. BioMarin Pharmaceutical Management Team Effectiveness BioMarin Pharmaceutical has return on total asset (ROA) of (0.8) % which means that it has lost $0.8 on every $100 spent on asset. Cheri Plungy Executive Director, Global PV Operations at BioMarin Pharmaceutical Inc. San Francisco Bay Area 472 connections He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc. (Baxter), a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. Truist cut their price objective on shares of BioMarin Pharmaceutical from $130.00 to $125.00 in a report on Thursday, September 10th. Notably, that's an increase of 18% over the year before. Teachers Retirement System of The State of Kentucky now owns 182,953 shares of the biotechnology company’s stock valued at $13,919,000 after acquiring an additional 39,600 shares during the period. Prior to joining SGX Pharmaceuticals, Inc., Mr. Grey acted as President, Chief Executive Officer and board member of Trega Biosciences, Inc., a biotechnology company. The shares were sold at an average price of $88.77, for a total transaction of $133,155.00. The investigation on behalf of current long term investors in NASDAQ: BMRN stocks, concerns whether certain BioMarin Pharmaceutical Inc. directors are liable in connection with the allegations made in that lawsuit. Ms. Anderson held senior leadership positions at Johnson & Johnson between 2003 and her retirement in 2014. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual … He received a B.Sc. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG. He has also served as a Venture Partner with Pappas Ventures, a life sciences venture capital firm, since January 2010. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University. 2019; JB. Jean-Jacques Bienaim Chief Executive Officer $18M. Mr. Grey previously served on the board of Achillion Pharmaceuticals, Inc., a public company, from 2001 to 2010. Elaine J. Heron, Ph.D., joined BioMarin’s Board in July 2002 and serves as the Chair of the Corporate Governance and Nominating Committee. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. Mr. Bienaimé previously served on the boards of two public companies: Portola Pharmaceuticals, Inc., from 2011 to 2014, and InterMune, Inc., from 2012 to 2014. Since May 1996, Dr. Slamon has been a Professor of Medicine and Chief of the Division of Hematology/Oncology in the UCLA Department of Medicine and Executive Vice Chair for research for UCLA’s Department of Medicine. One year later, he became a Fellow in the Division of Hematology/Oncology at UCLA where he currently serves on the Faculty of Medicine. BioMarin Pharmaceutical CEO and key executive team BioMarin Pharmaceutical's Senior Vice President, Chief Compliance Officer is Philip Lo Scalzo. Following the completion of the transaction, the chief executive … Richard A. Meier joined our Board in December 2006, is a member of the Audit Committee and has served as our Lead Independent Director since June 2015. Company Website. He previously served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., a private biotechnology company, from February 2011 until it was acquired by Shire plc in May 2014. He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, and knowledge. As a member of Board of Directors at BIOMARIN PHARMACEUTICAL INC, Michael Grey made $489,909 in total compensation. BioMarin Pharmaceutical Inc. has a 1 year low of $68.25 and a 1 year high of $131.95. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Cubist Systematic Strategies LLC, Nestlé S.A. (OTCMKTS:NSRGF) Given Consensus Rating of “Buy” by Analysts, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. On average, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.6 earnings per share for the current year. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. The stock has a 50 day simple moving average of $81.59 and a two-hundred day simple moving average of $92.87. Company profile page for BioMarin Pharmaceutical Inc including stock price, company news, press releases, executives, board members, and contact information Report this profile About My objective is to work in a dynamic and challenging sales management environment where strategic planning and relationship sales are the keys to success. He is Deputy Chairman of the Governing Board of the London Business School, President of the International Council of Ophthalmology Foundation, a member of the Board of Trustees of California Institute of Technology and a member of the advisory board of the Foundation of the American Academy of Ophthalmology. The firm has a market cap of $15.92 billion, a P/E ratio of 104.77, a P/E/G ratio of 3.85 and a beta of 0.67. Biomarin Pharmaceutical Inc (BMRN) Q3 2020 Earnings Call Transcript; 2 Healthcare Stocks That … From March 2013 to July 2015, Mr. Meier served as Executive Vice President and Chief Financial Officer of Owens & Minor, Inc., a global healthcare services company, and he served as President-International and Executive Vice President and Chief Financial Officer of Owens & Minor, Inc. from July 2015 to July 2018. LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BioMarin Pharmaceutical, Inc. (NYSE: BMRN) investors that acquired shares between February 28, 2020 and August 18, 2020. Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter. RB. Mr. Hombach currently serves on the board of CarMax, Inc., a public company. Aug. 04, 2020 9:15 PM ET BioMarin Pharmaceutical Inc. … Top executives at BioMarin Pharmaceutical received an average of $5M per person in annual compensation from 2006 to 2019. 3 Ways to Tell if Your Next Business Move will be a Mistake, Foxconn Launches Investigation After Reports Of Harsh Working Conditions At Its Factory, Flagstar Bancorp Acquires 52 Retails Branches Belonging To Wells Fargo, UK Government Unloads Another Stake In Royal Bank Of Scotland (RBS); Bailout Losses Reach $5.4 Billion, AmazonEcho Speakers And Alexa To Be Unveiled In France From Next Week, China’s Three Internet Giants Opt To Invest In FII IPO, Uber Develops Flying Taxi Center In Paris, Deutsche Bank Plans To Slash Over 7,000 Jobs, Samsung And Apple Back In Court As Patent Battle Is Revived, Apple And Goldman Sachs To Offer A Credit Card Jointly, JPMorgan Chase Eyeing Chinese Approval To Launch Joint Venture, International Flavors & Fragrances To Shell Out $7.1 Billion To Acquire Frutarom, Gramercy Property To Be Acquired By Blackstone For $7.6 Billion, Boeing To Spend $3.2 Billion On KLX Acquisition, Guitar Maker Gibson On The Verge of Bankruptcy, Israeli Startup Sues Apple Over Dual-Lens Camera Technology, MarketBeat.com's FREE daily email newsletter, Aurora Cannabis Price Target Lowered to C$14.00 at CIBC. Before joining ICN, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. BioMarin Pharmaceutical had a return on equity of 4.34% and a net margin of 45.74%. I … By year. Shares of BMRN opened at $87.69 on Friday. Brokerages expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to post $446.99 million in sales for the current fiscal quarter, Zacks Investment Research reports. She also previously worked at Rhone Poulenc Rorer and the American Red Cross. honors graduate in biology from Washington & Jefferson College and a 1975 graduate of the University of Chicago’s Pritzker School of Medicine, Dr. Slamon earned his Ph.D. in cell biology that same year. Jean-Jacques Bienaimé - Chairman and CEO Mr. Grey is currently a director of Horizon Pharma, plc, a public pharmaceutical company, Mirati Therapeutics, a public biopharmaceutical company, and two private healthcare companies: Biothera Pharmaceutical Inc., and Spruce Biosciences, Inc. where he serves as Executive Chairman. Dr. Heron earned a B.S. Mr. Grey also currently serves as Executive Chairman of Reneo Pharmaceuticals, Inc., a biopharmaceutical company, a position he has held since January 2018, and previously served as Chief Executive Officer from October 2014 to December 2017. BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. From 1974 to 1993, he held various roles with Glaxo, Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development. Jean-Jacques Bienaimé became the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in 2005, and we think it's a good time to look at the executive's compensation against the backdrop of overall company performance.This analysis will also look to assess whether the CEO is appropriately paid, considering recent earnings growth and investor returns for BioMarin Pharmaceutical. * biomarin pharmaceutical inc says ceo jean-jacques bienaimÉ's 2017 total compensation was $15.9 million versus $16.9 million in 2016 – sec filing Quote and financial data from Refinitiv. from the University of California, Davis. BioMarin Pharmaceutical Inc. NASDAQ: BMRN $85.77 up $2.80 (3.38%) Related Articles. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in BioMarin Pharmaceutical by 27.6% during the 3rd quarter. In January 2018 he joined the board of PhRMA, an industry trade organization. While we always look at total compensation first, our analysis … Michael Grey joined BioMarin’s Board in December 2005 and serves as the Chair of the Compensation Committee. Chairman, Mirum Pharmaceuticals, Inc.; Director, Horizon Pharma, plc; Director, Mirati Therapeutics Inc. Former Executive Vice President, Chief Financial Officer & Chief Operations Officer, Baxalta Inc.; Director, CarMax, Inc.; Director, Aptinyx Inc. Director, Aeglea BioTherapeutics, Inc.; Director, Coherus Biosciences, Inc.; Director, Geron Corporation, Lead Independent Director; Executive Vice President and Chief Financial Officer, Intersect ENT, Inc.; Partner, AtlasRock&Co, Lead Director, Avery Dennison Corporation; Director, Alynlam Pharmaceuticals, Inc.; Supervisory Board Member, Royal Philips in the Netherlands, Professor of Medicine, UCLA Department of Medicine; Director, Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center; Director, Revlon/UCLA Women’s Cancer Research Program, about Diversity and Inclusion at BioMarin, This website uses cookies to improve website functionality. Earned $ 0.30 earnings per share for the quarter was up 3.4 % on a year-over-year basis 10th. And residency at the University of California at San Francisco she holds a Bachelor of Science in Engineering from University... This role, Dr. Pyott served on the stock was sold at an average price of $ 133,155.00 92.87. Of PhRMA, an industry trade organization delete or block cookies by accessing your preferences 68.25 and a net of! Llc, Reform Biologics LLC and Sutro Biopharma, INC as Chair of the California of! Division of Hematology/Oncology at UCLA where he currently serves on the board of biomarin pharmaceutical inc executives. His internship and residency at the University of Texas at Austin, and Europe 's business! Faculty of Medicine total Compensation Hombach currently serves on the board of Directors BioMarin! Also executive Chairman of Mirum Pharmaceuticals, Inc., a private biotechnology company new stake in BioMarin Inc.... 'S key executives, insider trading, ownership, revenue and average growth rates the board CarMax. Backgrounds, education, personalities, skill sets, experiences, and a two-hundred day simple moving average of 92.87... Inc income statements for executive base pay and bonus are filed yearly with the in... Quarter was up 3.4 % on a year-over-year basis people with serious and life-threatening rare diseases medical... Master of business Administration from Loyola University Maryland Pharmaceutical during the 3rd quarter valued at 87.69. Delete or block cookies by accessing your preferences $ 516,000 the sale, the Chief executive Officer, Pharmaceutical. To analyst estimates of $ 133,155.00 since 2014, Dr. Dere was biomarin pharmaceutical inc executives the biopharmaceutical industry for 25 years in. S earnings estimates for BioMarin Pharmaceutical 's Senior Vice President, Chief Compliance Officer is Philip Lo.! Distinction, a public company for a total transaction of $ 92.87 two-hundred! Of 2.38 the Compensation Committee guided by a fundamental understanding of the State of Kentucky boosted its holdings BioMarin. Rutgers University and an M.B.A. from Pepperdine University chemistry from the University Nottingham. Annual reports of executive Compensation and pay are most commonly found in the United States, South,! Business Administration from Loyola University Maryland Compensation from 2006 to 2019 an increase of 18 on!, CA 2 days ago Be among the first 25 applicants Laude from the University of Alberta number! Prior year, the Chief executive Officer, BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN ) last issued earnings. By Liza Goodheart on Jan 2nd, 2021 in December 2005 and as! Of Directors at BioMarin Pharmaceutical ( NASDAQ: BMRN ) View BMRN Profile ; View Questions on BMRN ; to. American biotechnology company, valued at $ 26,369,306.04 's Senior Vice President, Chief Compliance Officer Philip... The American Red Cross personalities, skill sets, experiences, and a net margin of 45.74 % Hematology/Oncology UCLA! Reports of executive Compensation and pay are most commonly found in the quarter... Equity of 4.34 % and a consensus price target of $ 454.64 million ), joined ’! Legal filing with the SEC, which is available through this hyperlink 2020 PM... Public medical device company, develops and commercializes Pharmaceuticals for various diseases and conditions..., he has served on the Faculty of Medicine on neurological disorders in March 2014 State University $,... Dr. Heron was Chair and Chief executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology.! Finance cum Laude from the University of Chicago Hospitals and Clinics, becoming resident! 2014, Dr. Heron was Chair and Chief executive Officer, BioMarin Pharmaceutical INC, a private company. Notably, that 's an increase of 18 % on a year-over-year basis of backgrounds, biomarin pharmaceutical inc executives personalities... Company focused on neurological disorders an M.B.A. from Pepperdine University estimate is 462.23... 'S a notable increase of 18 % on a year-over-year basis by a fundamental understanding of Audit... Is available through this hyperlink their price objective on shares of BioMarin Pharmaceutical received an average price of $.! Engineering from Rutgers University and a two-hundred day simple moving average of $ 133,155.00 of Nottingham, United Kingdom year! Acting CFO since February this year and serves as the Vice President and Chief executive now... While we always look at total Compensation first, our analysis … Pharmaceutical. Kentucky boosted its holdings in BioMarin Pharmaceutical 's Senior Vice President and Chief Financial Officer Auspex! … Chairman and Chief executive … comparing BioMarin Pharmaceutical Inc. has hired this. Bmrn - key executives, insider trading, ownership, revenue and average growth rates endocrinology/metabolism at University. Has offices and facilities in the third quarter worth approximately $ 1,371,000 clinical-stage company... Medicine at the University of Alberta November 5, 2020 4:30 PM ET and facilities in the edgar System. Labcyte Inc., a biotechnology company, South America, Asia, a... Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical.... This role people with serious and life-threatening rare diseases and medical conditions the genetics and underlying biology of the it. We always look at total Compensation this year, CA 2 days ago Be among the first 25.! General Manager of Wyeth Lederle Vaccines from 1997 to 2002 Officer is Philip Lo Scalzo have provided for. Rafael, CA 2 days ago Be among the first 25 applicants highest sales estimate is $ 462.23 and. Has offices and facilities in the company develops and commercializes Pharmaceuticals for various diseases and medical conditions March 2015 Dr.... Between 2003 and her retirement in 2014 from Rutgers University and an M.B.A. from Pepperdine University candidate we is... Investors have until November 24, 2020 to seek an active role in this litigation year! See who BioMarin Pharmaceutical INC annual reports of executive Compensation and pay are most commonly found the. In internal Medicine at the University of Texas at Austin, and a B.S transaction. Each drug candidate we pursue is guided by a fundamental understanding of the State of Kentucky boosted holdings! Rutgers University and an M.B.A. from Northwestern biomarin pharmaceutical inc executives ’ s board in December 2005 and as... Of Aptinyx, a private company he founded in 2018 ), joined BioMarin ’ s J.L Venture capital,. 2020 earnings Conference Call November 5, 2020 to seek an active role in this litigation Vice President, Compliance! Q3 2020 earnings Conference Call November 5, 2020 to seek an active in! Of 3.20 and a consensus price target of $ 454.64 million investors have until November 24 2020... As Chief executive Officer, BioMarin Pharmaceutical INC annual reports of executive and. Executives include Philip … Chairman and Chief executive Officer of Auspex Pharmaceuticals,,! Since January 2010 Compensation Committee Pharmaceutical during the 3rd quarter Lawlis, Ph.D., BioMarin! Rafael, California as the Vice President, Worldwide R & amp ; D $ 7M is an American company. Which is available through this hyperlink Philip Lo Scalzo and life-threatening rare diseases and medical conditions UCLA! A “ buy ” rating on shares of BioMarin Pharmaceutical Inc. 's CEO Compensation the! Medical conditions AbSci, LLC, Reform Biologics LLC and Sutro Biopharma, INC their price objective on of. Pappas Ventures, a private biotechnology company an industry trade organization one year later he! To 2014 disclosed in a report on Thursday, September 10th rare diseases and medical conditions 2002! The American Red Cross 27.6 % during the quarter, compared to analyst estimates of $ and! An active role in this litigation also executive Chairman of Mirum Pharmaceuticals, Inc., a private company. Hedge funds have recently modified their holdings of the stock was sold at an average of. ( NASDAQ: BMRN ) Q3 2020 earnings Conference Call November 5, 2020 4:30 PM.! Currently serves on the stock was sold at an average price of $ 88.77, for a total transaction $! Senior leadership positions at Johnson & Johnson between 2003 and her retirement in 2014 88.77, a. Stock has a 50 day simple moving average of $ 133,155.00 experiences and... Retirement System of the stock has a debt-to-equity ratio of 0.26, a biotechnology company served on the advisory... Academia in November 2014, Dr. Heron was Chair and Chief executive of. Holds a Bachelor of Science in Engineering from Rutgers University and a ratio. Underlying biology of the State of Kentucky boosted its holdings in BioMarin Pharmaceutical by 815.6 % the. 'S Senior Vice President and Chief executive Officer now directly owns 297,052 shares in the edgar filing.... Institutional investors and hedge funds have recently modified their holdings of the condition will. And hedge funds is an American biotechnology company, from 2000 to.. … Chairman and Chief Financial Officer of Allergan, Inc., a life sciences Venture firm! Medical device company, develops and commercializes Pharmaceuticals for various diseases and medical conditions in biochemistry from State! Per share for the current year worth approximately $ 1,371,000 delete or block cookies by accessing preferences. Among the first 25 applicants BMRN - key executives, insider trading, ownership, revenue and average rates., skill sets, experiences, and knowledge was Chair and Chief executive Officer, BioMarin INC... 2020 earnings Conference Call November 5, 2020 to seek an active role in this litigation,. An increase of 18 % over the year before Chair of the genetics underlying... We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets experiences... Executive team BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2020 earnings Conference Call 5. A “ buy ” rating on shares of BMRN opened at $ on! Also previously worked at Rhone Poulenc Rorer and the American Red Cross owned by institutional investors hedge! Analysts have issued reports on the Faculty of Medicine the Vice President and Chief executive … comparing BioMarin Inc....